Business Wire

NEDGROUP-INVESTMENTS

Share
Nedgroup Investments expands boutique advantage range, onboards David Roberts and Alex Ralph to launch fixed income boutique

Nedgroup Investments, a global asset manager with over $20bn AUM, is launching an in-house multi-boutique platform which will feature a growing range of active investment strategies characterised by deep alignment of client and fund manager interests.

Tom Caddick, Managing Director of Nedgroup Investments (International) commented: “It's harder for boutiques to set up now because of the onerous regulatory requirements and the difficulty of raising sufficient capital. We want to facilitate start-up boutiques to better serve the needs of our clients and provide a wider range of investment opportunity. We can create a more diverse fund management sector for the benefit of the end investor. I’m thrilled to launch our innovative structure with two conviction managers I have known and respected for over 20 years.”

Fixed-income veterans David Roberts and Alex Ralph will run an active global bond fund as the first launch of these in-house managed strategies.

Roberts commented: “I have returned to active investing because market conditions are too compelling to ignore. I have always had conviction to invest when risk and reward are in the client’s favour. After a couple of years when return expectations were negative, we are back in an environment where fixed income is once again a diversifier, a very attractive alternative to equities. The old normal.”

Ralph adds: “Many have been waiting a decade for this type of entry point and the possibility of earning significant, long term positive returns without the need to venture into the dark, equity-like corners of the bond market.”

Addressing the attractions of the firm, Roberts commented: “Nedgroup Investment’s has a long-standing belief in the benefits to investors of boutique models and they share my client-centric approach. Those were the deciding factors for me. It is rare these days to find a business willing to innovate and support a boutique from inception.”

Apiramy Jeyarajah, who joined Nedgroup Investments as Chief Commercial Officer in April 2023, added: “Starting an investment boutique is increasingly difficult. We are excited to offer clients access to compelling teams, complementing the existing boutiques on our platform. Nurturing opportunities with experienced fund managers will help investors benefit from increased choice and a competitive edge.”

About Nedgroup Investments

Nedgroup Investments is a global asset manager with over $20 billion AUM with its international business led from London and global headquarters in Cape Town. Nedgroup Investments is known for its award winning ‘Best of Breed’ partnership model with leading boutique managers in London, Los Angeles, New York and Sydney, offering investors access to the world’s best managers and their funds.

The Nedgroup Investments Boutique Advantage Philosophy

Nedgroup Investments’ fundamental belief is that the best performing investment funds are run by managers that are autonomous, focused and have a concentrated alignment of interests with the unit-holders of their fund.

Fund Range

Nedgroup Investments has two fund ranges – Nedgroup Investments Funds Plc (launched in November 2008) and Nedgroup Investments Multifunds Plc (launched in August 2011).

About David Roberts

David Roberts is a fixed income investor with over 30 years’ experience. He is known for his skin in the game investment style and was previously head of fixed income at Liontrust until early 2022. Previously, he was a fund manager with Aegon Asset Management (formerly Kames Capital) where he was also co-head of fixed income and worked for 14 years. Prior to that, he held roles at Britannia Investment Managers and Lloyds Bank.

About Alex Ralph

Alex Ralph is a highly respected fixed-income fund manager with over two decades of experience in the industry. She is widely recognized for her strong track record of success and is considered one of the leading fixed-income investors of her generation. Alex was most recently a partner at Artemis Investment Management where she helped set up the bond desk launching the Strategic bond fund in 2005. In 2014, she was also appointed lead fund manager on the Artemis high income fund. The desk managed some £3 billion in credit by the end of her tenure at Artemis. Alex holds a BSc in Economics from London School of Economics and is a CFA Charter holder.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230509006145/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release

‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye